Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Top Cited Papers
- 1 August 2019
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 20 (8) , 1124-1135
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK
This publication has 21 references indexed in Scilit:
- The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast CancersMolecular Cancer Therapeutics, 2015
- HER2 expression status in diverse cancers: review of results from 37,992 patientsCancer and Metastasis Reviews, 2015
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985Molecular Pharmaceutics, 2015
- Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug PlatformMolecular Cancer Therapeutics, 2014
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancerCancer Chemotherapy and Pharmacology, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987